Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kyndryl Holdings Inc (KD) vs Summit Therapeutics Inc (SMMT) Price & Performance

Kyndryl Holdings IncTrade
Summit Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Kyndryl Holdings Inc vs Summit Therapeutics Inc — how do they compare? Kyndryl Holdings Inc trades at $12.91 (market cap $2.91B), while Summit Therapeutics Inc trades at $15.22 (market cap $12.06B). The key difference: Summit Therapeutics Inc is far larger — about 4.1× Kyndryl Holdings Inc's market cap. Which is the better fit depends on your goals.

KDSMMT
Market Cap
$2.91B$12.06B
Sector
TechnologyHealth
52-Week High
$33.14$26.98
52-Week Low
$10.59$12.55
Enterprise Value
$5.74B$11.39B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kyndryl Holdings Inc

Kyndryl (KD) trades at $12.87, down 5.58% on the day, with a neutral technical signal and mixed earnings history. The company reported a net income of $252 million in 2025, reversing prior losses, and maintains strong operating cash flow of $942 million. Recent news includes an acquisition to boost AI services and Q1 2027 results showing a revenue miss but an EBITDA beat.

The stock presents a cautious opportunity with a consensus price target of $13.50, offering modest upside. Risks include inconsistent earnings, high debt levels, and ongoing investigations. Analyst sentiment is predominantly hold, reflecting uncertainty amid strategic shifts toward growth areas like AI and cloud partnerships.

Summit Therapeutics Inc

Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.

The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Kyndryl Holdings Inc

Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.

Read more on KD

About Summit Therapeutics Inc

Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.

Read more on SMMT